CD83 is a marker of AML LICs, and therapeutic targeting using CD83-CAR T cells has shown preliminary success in humanized mouse models of AML [74], suggesting it could be a potential therapeutic target in JMML. This evidence concerns the gene CD83 and juvenile myelomonocytic leukemia.